Clinic
Alamance Regional Medical Center, INC.
Alamance Regional Medical Center, INC. was paid $30.90M by Medicaid between Jan 2018 and Dec 2024, across 126 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.
33Billing provider infoALAMANCE REGIONAL MEDICAL CENTER, INC.
BURLINGTON, NC 27215
BURLINGTON, NC 27215
33aNPI1326010273assigned 02/05/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$30.90M
24GClaims503,171
24DCodes billed126
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in North Carolina
Rank by total paid#1 of 56
Median peer was paid$409K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HAMMOND, SALLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,735 | $4.04M | |
| 2019 | 63,754 | $3.58M | |
| 2020 | 47,413 | $2.64M | |
| 2021 | 64,684 | $3.15M | |
| 2022 | 64,674 | $4.59M | |
| 2023 | 87,228 | $5.77M | |
| 2024incomplete | 100,683 | $7.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 31% | 30,380 | 27,071 | $9.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 32,440 | 30,003 | $7.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 30,244 | 28,377 | $5.03M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.3% | 1,720 | 1,615 | $1.63M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 19,784 | 16,247 | $912K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.9% | 5,387 | 4,873 | $904K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 9,073 | 7,636 | $655K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.5% | 9,843 | 7,004 | $461K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 10,128 | 9,327 | $439K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 19,038 | 16,474 | $396K |
| 80053 | Comprehensive metabolic panel | 1.2% | 35,213 | 30,305 | $360K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,928 | 1,728 | $238K |
114 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,968 | $226K |
| 85027 | <1% | 31,656 | $215K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,462 | $166K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,423 | $153K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 789 | $145K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,038 | $124K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,566 | $123K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,015 | $113K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,790 | $107K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,949 | $101K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,543 | $86K |
| J3490 | Unclassified drugs | <1% | 28,645 | $80K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,921 | $80K |
| G0378 | Hospital observation service, per hour | <1% | 547 | $64K |
| 84484 | <1% | 8,629 | $63K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,377 | $59K |
| 81001 | <1% | 17,782 | $58K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,220 | $58K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,133 | $54K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 222 | $49K |
| 83690 | <1% | 6,421 | $49K | |
| A9270 | Non-covered item or service | <1% | 92,891 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 110 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 819 | $44K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 858 | $41K |
| 81025 | <1% | 4,672 | $36K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,313 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 517 | $30K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,015 | $26K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,151 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,455 | $20K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 226 | $20K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 263 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,600 | $14K |
| 93320 | <1% | 221 | $14K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 179 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 363 | $12K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 93 | $11K |
| 70300 | <1% | 598 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 788 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 274 | $10K |
| 87400 | <1% | 383 | $10K | |
| 93325 | <1% | 221 | $9K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $9K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 57 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 854 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,301 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,298 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 478 | $6K |
| 87081 | <1% | 905 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 108 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,926 | $6K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 448 | $6K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 35 | $5K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 91 | $5K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 423 | $5K |
| 80061 | Lipid panel | <1% | 265 | $4K |
| 77412 | <1% | 153 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 290 | $3K |
| 76000 | <1% | 124 | $3K | |
| 83525 | <1% | 207 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 143 | $3K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 51 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,008 | $3K |
| 82728 | <1% | 252 | $2K | |
| 77336 | <1% | 60 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 231 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 71 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 58 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 28 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,053 | $2K |
| 99152 | <1% | 42 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 57 | $1K |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 298 | $1K |
| 83550 | <1% | 205 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 13 | $1K |
| 83540 | <1% | 207 | $1K | |
| 29581 | <1% | 43 | $903.57 | |
| 87210 | <1% | 173 | $871.06 | |
| 81003 | <1% | 373 | $867.36 | |
| 36410 | <1% | 34 | $769.36 | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 18 | $693.39 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 54 | $632.66 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 46 | $618.60 |
| 36591 | <1% | 61 | $552.73 | |
| 84702 | <1% | 52 | $552.30 | |
| 70310 | <1% | 13 | $523.35 | |
| 87503 | <1% | 56 | $520.65 | |
| 86756 | <1% | 22 | $495.13 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 399 | $473.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 154 | $453.01 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $449.55 |
| 87481 | <1% | 12 | $449.55 | |
| 87511 | <1% | 12 | $437.19 | |
| 83880 | <1% | 14 | $375.24 | |
| 87486 | <1% | 14 | $336.16 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 72 | $301.47 |
| 99201 | <1% | 19 | $215.55 | |
| 84439 | <1% | 14 | $157.36 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 861 | $104.86 |
| 85379 | <1% | 12 | $102.98 | |
| 84436 | <1% | 14 | $100.52 | |
| 80076 | <1% | 15 | $71.12 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 25 | $64.69 |
| 36415 | Collection of venous blood by venipuncture | <1% | 35 | $60.96 |
| 85045 | <1% | 12 | $59.88 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13 | $33.61 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 186 | $31.57 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 12 | $30.50 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 20 | $19.18 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 17 | $5.08 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 13 | $0.00 |
| 1159F | 0% | 14 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 216 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAMMOND, SALLY (EXECUTIVE DIRECTOR, OPERATIONS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.